Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Consensus statement on the use of rituximab in patients with rheumatoid arthritis.

Literature DB >> 17068064

Consensus statement on the use of rituximab in patients with rheumatoid arthritis.

J S Smolen¹, E C Keystone, P Emery, F C Breedveld, N Betteridge, G R Burmester, M Dougados, G Ferraccioli, U Jaeger, L Klareskog, T K Kvien, E Martin-Mola, K Pavelka.

Abstract

A large number of experts experienced in the treatment of rheumatoid arthritis were involved in formulating a consensus statement on the use of B cell-targeted treatment with rituximab in patients with rheumatoid arthritis. The statement was supported by data from randomised controlled clinical trials and the substantial literature on oncology. The statement underwent three rounds of discussions until its ultimate formulation. It should guide clinicians in the use of this newly approved biological agent in treating patients with rheumatoid arthritis.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2006 PMID： 17068064 PMCID： PMC1798500 DOI： 10.1136/ard.2006.061002

Source DB: PubMed Journal: Ann Rheum Dis ISSN： 0003-4967 Impact factor: 19.103

34 in total

Review 1. Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update.

Authors: L Kunkel; A Wong; T Maneatis; J Nickas; T Brown; A Grillo-López; M Benyunes; B Grobman; R O Dillman
Journal: Semin Oncol Date: 2000-12 Impact factor: 4.929

Review 2. Clinical outcome measures in rheumatoid arthritis.

Authors: P L van Riel; A M van Gestel
Journal: Ann Rheum Dis Date: 2000-11 Impact factor: 19.103

3. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma.

Authors: A Bermúdez; F Marco; E Conde; E Mazo; M Recio; A Zubizarreta
Journal: Haematologica Date: 2000-08 Impact factor: 9.941

Review 4. Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis.

Authors: J S Smolen; F C Breedveld; G R Burmester; B Combe; P Emery; J R Kalden; L Klareskog; R N Maini; R Numo; L B van De Putte; P L van Riel; V Rodriguez-Valverde
Journal: Ann Rheum Dis Date: 2000-07 Impact factor: 19.103

5. Patients' views on the quality of health care for rheumatoid arthritis.

Authors: H Lempp; D L Scott; G H Kingsley
Journal: Rheumatology (Oxford) Date: 2006-04-21 Impact factor: 7.580

6. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

Authors: Stanley B Cohen; Paul Emery; Maria W Greenwald; Maxime Dougados; Richard A Furie; Mark C Genovese; Edward C Keystone; James E Loveless; Gerd-Rüdiger Burmester; Matthew W Cravets; Eva W Hessey; Timothy Shaw; Mark C Totoritis
Journal: Arthritis Rheum Date: 2006-09

7. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.

Authors: François Boué; Jean Gabarre; Christian Gisselbrecht; Jacques Reynes; Antoine Cheret; Fabrice Bonnet; Eric Billaud; Martine Raphael; Remi Lancar; Dominique Costagliola
Journal: J Clin Oncol Date: 2006-08-08 Impact factor: 44.544

Review 8. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.

Authors: Winnie Yeo; Philip J Johnson
Journal: Hepatology Date: 2006-02 Impact factor: 17.425

9. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab.

Authors: T Hamaki; M Kami; E Kusumi; J Ueyama; S Miyakoshi; S Morinaga; Y Mutou
Journal: Am J Hematol Date: 2001-12 Impact factor: 10.047

10. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

Authors: Paul Emery; Roy Fleischmann; Anna Filipowicz-Sosnowska; Joy Schechtman; Leszek Szczepanski; Arthur Kavanaugh; Artur J Racewicz; Ronald F van Vollenhoven; Nicole F Li; Sunil Agarwal; Eva W Hessey; Timothy M Shaw
Journal: Arthritis Rheum Date: 2006-05

45 in total

1. Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection.

Authors: Sarah K Browne; Rifat Zaman; Elizabeth P Sampaio; Kamonwan Jutivorakool; Lindsey B Rosen; Li Ding; Minjal J Pancholi; Lauren M Yang; Debra Long Priel; Gulbu Uzel; Alexandra F Freeman; Carlton E Hayes; Roger Baxter; Stuart H Cohen; Steven M Holland
Journal: Blood Date: 2012-03-08 Impact factor: 22.113

Consensus statement on the use of rituximab in patients with rheumatoid arthritis.

Review 1. Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update.

Review 2. Clinical outcome measures in rheumatoid arthritis.

3. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma.

Review 4. Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis.

5. Patients' views on the quality of health care for rheumatoid arthritis.

6. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

7. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.

Review 8. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.

9. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab.

10. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

1. Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection.

2. Indications of rituximab in autoimmune diseases.

3. Rituximab: a review of dermatological applications.

Review 4. Biologic therapy for refractory scleritis: a new treatment perspective.

5. Escalating immunotherapy of multiple sclerosis.

6. Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosis.

7. [Recommendations for use of rituximab in patients with rheumatoid arthritis].

8. Rituximab in routine care of severe active rheumatoid arthritis : A prospective, non-interventional study in Germany.

9. [How effective is rituximab in rheumatoid arthritis?: lessons learned from clinical practice].

10. NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis.